Axsome Therapeutics (AXSM) Revenue & Revenue Breakdown
Axsome Therapeutics Revenue Highlights
Latest Revenue (Y)
$270.60M
Latest Revenue (Q)
$87.17M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Axsome Therapeutics Revenue by Period
Axsome Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $270.60M | 440.80% |
| 2022-12-31 | $50.04M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Axsome Therapeutics generated $270.60M in revenue during NA 2023, up 440.80% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Axsome Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $87.17M | 16.22% |
| 2024-03-31 | $75.00M | 4.85% |
| 2023-12-31 | $71.53M | 23.77% |
| 2023-09-30 | $57.79M | 23.76% |
| 2023-06-30 | $46.70M | -50.62% |
| 2023-03-31 | $94.58M | 288.06% |
| 2022-12-31 | $24.37M | 44.67% |
| 2022-09-30 | $16.85M | 91.00% |
| 2022-06-30 | $8.82M | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | - |
Axsome Therapeutics generated $87.17M in revenue during Q2 2024, up 16.22% compared to the previous quarter, and up 92.17% compared to the same period a year ago.
Axsome Therapeutics Revenue Breakdown
Axsome Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 |
|---|---|
| Product | $202.46M |
| License | $65.73M |
| Royalty | $2.40M |
Axsome Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (74.82%), License (24.29%), and Royalty (0.89%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|
| Royalty | $903.00K | $783.00K | $667.00K | $683.00K | $272.00K |
| Product | $74.10M | $70.75M | $57.13M | $46.02M | $28.57M |
| License | - | - | $65.73M | $65.73M | - |
Axsome Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (98.80%), and Royalty (1.20%).
Axsome Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| UNITED STATES | $197.22M | - |
| Non-US | $65.73M | $900.00K |
Axsome Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (75.00%), and Non-US (25.00%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|
| Non-US | $903.00K | - | $65.73M | $600.00K | $1.70M |
| UNITED STATES | $73.27M | $141.44M | $55.78M | - | - |
Axsome Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (98.78%), and Non-US (1.22%).
Axsome Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| ACAD | ACADIA Pharmaceuticals | $726.44M | $241.96M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| AXSM | Axsome Therapeutics | $270.60M | $87.17M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| MCRB | Seres Therapeutics | $126.33M | - |
| VKTX | Viking Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| MDGL | Madrigal Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
AXSM Revenue FAQ
What is Axsome Therapeutics’s yearly revenue?
Axsome Therapeutics's yearly revenue for 2023 was $270.6M, representing an increase of 440.80% compared to 2022. The company's yearly revenue for 2022 was $50.04M, representing an increase of 100.00% compared to 2021. AXSM's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Axsome Therapeutics’s quarterly revenue?
Axsome Therapeutics's quarterly revenue for Q2 2024 was $87.17M, a 16.22% increase from the previous quarter (Q1 2024), and a 86.65% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $75M, a 4.85% increase from the previous quarter (Q4 2023), and a -20.70% decrease year-over-year (Q1 2023). AXSM's quarterly revenue for Q4 2023 was $71.53M, a 23.77% increase from the previous quarter (Q3 2023), and a 193.50% increase year-over-year (Q4 2022).
What is Axsome Therapeutics’s revenue growth rate?
Axsome Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.
What are Axsome Therapeutics’s revenue streams?
Axsome Therapeutics's revenue streams in c 23 are Product, License, and Royalty. Product generated $202.46M in revenue, accounting 74.82% of the company's total revenue License generated $65.74M in revenue, accounting 24.29% of the company's total revenue Royalty generated $2.4M in revenue, accounting 0.89% of the company's total revenue
What is Axsome Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Axsome Therapeutics was Product. This segment made a revenue of $202.46M, representing 74.82% of the company's total revenue.